Dermira Inc.:製薬企業の製品開発パイプライン動向2014

◆英語タイトル:Dermira Inc. - Product Pipeline Review - 2014
◆商品コード:GMDHC05380CDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年7月10日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥168,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥504,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Dermira Inc. – Product Pipeline Review – 2014

Summary

Global Markets Direct’s, ‘Dermira Inc. – Product Pipeline Review – 2014’, provides an overview of the Dermira Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dermira Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Dermira Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Dermira Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Dermira Inc.’s pipeline products

Reasons to buy

- Evaluate Dermira Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Dermira Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Dermira Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Dermira Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dermira Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Dermira Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Dermira Inc. Snapshot 4
Dermira Inc. Overview 4
Key Information 4
Key Facts 4
Dermira Inc. – Research and Development Overview 5
Key Therapeutic Areas 5
Dermira Inc. – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Pipeline Products – Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Dermira Inc. – Pipeline Products Glance 11
Dermira Inc. – Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Dermira Inc. – Drug Profiles 13
DRM-01 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
DRM-02 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
DRM-04 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
lemuteporfin 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Dermira Inc. – Pipeline Analysis 18
Dermira Inc. – Pipeline Products by Target 18
Dermira Inc. – Pipeline Products by Route of Administration 19
Dermira Inc. – Pipeline Products by Molecule Type 20
Dermira Inc. – Pipeline Products by Mechanism of Action 21
Dermira Inc. – Recent Pipeline Updates 22
Dermira Inc. – Dormant Projects 24
Dermira Inc. – Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables
Dermira Inc., Key Information 4
Dermira Inc., Key Facts 4
Dermira Inc. - Pipeline by Indication, 2014 6
Dermira Inc. - Pipeline by Stage of Development, 2014 7
Dermira Inc. - Monotherapy Products in Pipeline, 2014 8
Dermira Inc. - Partnered Products in Pipeline, 2014 9
Dermira Inc. - Partnered Products/ Combination Treatment Modalities, 2014 10
Dermira Inc. - Phase II, 2014 11
Dermira Inc. - Phase I, 2014 12
Dermira Inc. - Pipeline by Target, 2014 18
Dermira Inc. - Pipeline by Route of Administration, 2014 19
Dermira Inc. - Pipeline by Molecule Type, 2014 20
Dermira Inc. - Pipeline Products by Mechanism of Action, 2014 21
Dermira Inc. - Recent Pipeline Updates, 2014 22
Dermira Inc. - Dormant Developmental Projects,2014 24

List of Figures
Dermira Inc. - Pipeline by Top 10 Indication, 2014 6
Dermira Inc. - Pipeline by Stage of Development, 2014 7
Dermira Inc. - Monotherapy Products in Pipeline, 2014 8
Dermira Inc. - Pipeline by Top 10 Target, 2014 18
Dermira Inc. - Pipeline by Top 10 Route of Administration, 2014 19
Dermira Inc. - Pipeline by Top 10 Molecule Type, 2014 20
Dermira Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 21

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[Dermira Inc.:製薬企業の製品開発パイプライン動向2014]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆